CNM-Au8
- Generic Name
- CNM-Au8
- Drug Type
- Biotech
Intermediate Expanded Access Protocol CNMAu8.EAP04
- Conditions
- ALSAmyotrophic Lateral SclerosisPALS
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Clene Nanomedicine
- Registration Number
- NCT06408727
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Columbia Unniversity, New York, New York, United States
Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Clene Nanomedicine
- Registration Number
- NCT05281484
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸UC Irvine, Orange, California, United States
🇺🇸Sutter Health (Enrollment is full, not recruiting), San Francisco, California, United States
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 55
- Registration Number
- NCT04626921
- Locations
- 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺Menzies Institute for Medical Research, Hobart, TAZ, Australia
🇦🇺Sydney Brain Mind Centre, Camperdown, New South Wales, Australia
HEALEY ALS Platform Trial - Regimen C CNM-Au8
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 161
- Registration Number
- NCT04414345
- Locations
- 🇺🇸
Healey Center for ALS at Mass General, Boston, Massachusetts, United States
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 45
- Registration Number
- NCT04098406
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺University of Sydney Brain and Mind Centre, Sydney, New South Wales, Australia
Intermediate Expanded Access Protocol CNMAu8.EAP03
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Clene Nanomedicine
- Registration Number
- NCT04081714
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple SclerosisOptic NeuropathyOptic; Neuritis, With Demyelination
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 73
- Registration Number
- NCT03536559
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇦🇺John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Sydney Brain Mind Centre, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.